Tesamorelin vs AOD-9604: Which Fat Loss Peptide Actually Holds Up in 2026?

Tesamorelin and AOD-9604 are both peptides tied to fat loss, but they are not close cousins. Tesamorelin is an FDA-approved GHRH analog that shrinks visceral belly fat in a specific patient group. AOD-9604 is a growth-hormone fragment that failed its main weight-loss trial and never became a drug. pru does not offer either one. For fat loss, pru offers compounded GLP-1 options instead. If you are researching this to get ahead of your metabolic health, that instinct is worth trusting.

Tesamorelin vs AOD-9604, in one look

Tesamorelin has real, FDA-approved clinical data for one narrow use: shrinking visceral belly fat in people with HIV-associated lipodystrophy. AOD-9604 has a much thinner record. It went through human trials for obesity and did not beat placebo on weight loss, so it was shelved. If you want the short version: tesamorelin is a proven visceral-fat tool for a specific medical use, and AOD-9604 is a research-grade peptide with promising lab science that never panned out in people.

Neither peptide is offered by pru. Both live outside the products a physician can prescribe through pru today. For fat loss and metabolic health, pru offers compounded semaglutide and compounded tirzepatide, which have far larger, more recent human weight-loss data.

How the two peptides compare at a glance

Here is the core contrast. One is a stabilized copy of a natural hormone signal. The other is a snipped-off piece of growth hormone. Their evidence and legal status are worlds apart.

Want the deeper dives? See the tesamorelin guide and the AOD-9604 guide.

What tesamorelin is and how it works

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). It is the natural GHRH sequence with a small chemical group added to the front end, which slows how fast the body breaks it down. That tweak lets the signal last longer than natural GHRH.

Instead of injecting growth hormone directly, tesamorelin tells your pituitary gland to release your own growth hormone in a more natural, pulsing pattern. That growth hormone raises IGF-1, and the combined effect pulls down visceral fat, the deep belly fat wrapped around your organs. Visceral fat cells carry lots of growth-hormone receptors, so they respond strongly. Subcutaneous fat, the fat just under your skin, responds much less.

The FDA approved tesamorelin in 2010 under the brand name Egrifta for HIV-associated lipodystrophy, a condition where excess visceral fat builds up. That is its only approved use. It is not FDA-approved as a general weight-loss drug. Dosing details are covered in the tesamorelin dosage explainer.

What the tesamorelin trials actually showed

Tesamorelin's reputation rests on solid clinical work. The landmark trial was published in the New England Journal of Medicine, and follow-up studies backed it up.

The takeaway: the visceral-fat drop was real, selective, and drug-dependent. It reversed when people stopped, which tells researchers the peptide was doing the work. But note the setting. This was a specific patient group with a specific fat problem, not everyday weight loss.

What AOD-9604 is and why it stalled

AOD-9604 is a short fragment taken from the tail end of human growth hormone, amino acids 176 to 191, with one extra piece added to the front. It was developed at Monash University in Australia in the 1990s. The goal was clever: isolate the fat-burning part of growth hormone while leaving out the growth-promoting and blood-sugar effects.

In animal and lab studies, AOD-9604 looked promising. It appeared to boost fat breakdown and fat burning without raising IGF-1. That lab story is why the peptide still gets attention today. The problem is what happened next.

AOD-9604 went through six human clinical trials involving roughly 900 people. Its safety looked clean, no worse than placebo. But in its main, adequately powered obesity trial, it did not produce statistically significant weight loss compared to placebo. The developer did not advance it to late-stage trials, and it was set aside as a weight-loss drug candidate around 2007. See the AOD-9604 dosage page for how it is studied today.

GHRH analog vs HGH fragment: why the category matters

This is the heart of the ghrh vs hgh fragment question. The two peptides sit in different families, and that shapes everything about them.

• Tesamorelin (GHRH analog) works upstream. It nudges your own hormone system to release growth hormone naturally, then lets that hormone do the downstream work on visceral fat.
• AOD-9604 (HGH fragment) was designed to act more directly, as a standalone fat-burning signal, without lifting growth hormone or IGF-1 at all.
• Tesamorelin cleared the bar the FDA sets for approval in its indication. AOD-9604 never did, because its human weight-loss results fell short.

So when people ask which is the best fat loss peptide, the picture is nuanced. Tesamorelin has the stronger evidence, but only for visceral fat in a specific condition. AOD-9604 has an appealing theory and a weak human track record. Neither is a broad, proven weight-loss solution for the general public.

Where peptide fat loss sits in 2026

Interest in fat-loss peptides has exploded, and a lot of it rides on the wave created by GLP-1 medications. Those are the drugs with the biggest, most recent human weight-loss data, and they have reshaped what people expect from a metabolic tool.

For most people chasing steady fat loss, the conversation has moved toward GLP-1 options with strong, current evidence. That is where pru focuses. See semaglutide vs tirzepatide and the best peptides for weight loss overview to place these tools side by side.

Safety, legality, and the grey market

Access is where these two peptides get risky. Tesamorelin is a real prescription drug, but only for its approved HIV indication, so most people cannot get it prescribed for general fat loss. AOD-9604 is not an approved drug at all. It holds a food-ingredient GRAS designation, which speaks to basic safety as an ingredient but says nothing about it working as a therapy, and it is under FDA review for compounding.

This is exactly why pru does not offer either peptide. When a compound lacks a legitimate compounded pathway, the responsible answer is to say so plainly rather than route you to an unregulated vendor.

How pru approaches fat loss peptides

pru is a telehealth platform for compounded peptides. Physicians review and prescribe, and FDA-regulated 503A compounding pharmacies fill the prescriptions. You select the option you are interested in, guided by pru's content, and the physician confirms whether it fits you clinically. The doctor does not pick a drug for you off a menu.

On fat loss specifically: pru does not offer tesamorelin or AOD-9604. What pru does offer are compounded semaglutide and compounded tirzepatide, pharmacy-grade GLP-1 options with the same active ingredients as the well-known branded medications. These are compounded products, not the branded drugs themselves.

Pricing is simple. For about $50 a month membership, peptides are provided at cost, itemized, with no member markup. A higher dose costs a bit more because it is more medication, never because of a markup.

Being proactive about your metabolic health is a smart, responsible step, and pru exists to make that informed choice the accessible one: licensed physicians, pharmacy-grade medicine, and at-cost pricing put the smart path within reach. See pricing and the fat loss and metabolism catalog for what is actually available, and take the next step when you are ready.

Related reading and next steps

Keep exploring peptides and GLP-1 options with these guides.

• Tesamorelin guide
• AOD-9604 guide
• Best peptides for weight loss
• Semaglutide vs tirzepatide
• GLP-1 weight loss timeline
• MOTS-c guide

Ready to see what pru actually offers? Browse the fat loss and metabolism catalog.

Common questions